icon-folder.gif   Conference Reports for NATAP  
 
  EASL 46th Annual Meeting
March 30th - April 3rd 2011
Berlin, Germany
Back grey_arrow_rt.gif
 
 
 
A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection
 
 
  Reported by Jules Levin EASL 2011 Berlin March 31-Apr 2
 
E Lawitz,1 I Jacobson,2 E Godofsky,3 G Foster,4 R Flisiak,5 M Bennett,6 M Ryan,7 JM Pawlotsky,8 Hinkle,9 J Simpson,9 J McHutchison,9 D Oldach,9 and M DeMicco10 1Alamo Medical Research, San Antonio, TX, USA; 2Weill Medical College of Cornell University, NY, NY, USA; 3Bach and Godofsky Infectious Diseases, Sarasota, FL, USA; 4Barts and The London Hopsital, London, UK; 5Klinika Chorob Zakaznych I Hepatologii, Bialystok, Poland; 6Medical Associates Research Group, San Diego, CA, USA; 7Digestive and Liver Disease Specialists, Norfolk, VA, USA; 8Henri Mondor Hospital, Paris, France; 9Gilead Sciences, Inc., Foster City, CA, USA; 10Advanced Clinical Research Institute, Anaheim, CA, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif